Cover Image
市場調查報告書

內臟器官·組織的移植及替代技術產品市場

Organ and Tissue Transplantation and Alternatives

出版商 BCC Research 商品編碼 208646
出版日期 內容資訊 英文 196 Pages
訂單完成後即時交付
價格
Back to Top
內臟器官·組織的移植及替代技術產品市場 Organ and Tissue Transplantation and Alternatives
出版日期: 2015年03月25日 內容資訊: 英文 196 Pages
簡介

全球移植產品,設備,醫藥品市場在2014年達到了556億美元。一般認為到2020年前將以年複合成長率6.8%的速度擴大,到2015年達到629億美元,2020年達到881億美元的規模。

本報告提供器官移植·組織移植及替代技術產品的市場之內臟器官·組織別詳細調查分析,提供產業概要,移植流程,各種法規,移植相關產品·醫藥品類別的市場實際成果·預測(∼2020),並彙整各種移植手術·替代法,主要企業簡介等資訊,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 產業概要

  • 移植的歷史
  • 產業內的企業收購
  • 內臟器官·組織移植的必要零組件
  • 提供流程概要
  • 移植流程
  • 固態內臟器官
  • 美國的組織移植
  • 美國國外的移植趨勢
  • 美國國外的生物及屍體內臟器官·組織提供趨勢
  • 全球固態器官移植
  • 供給限制阻礙移植
  • 產業促進成長要素
  • 產業阻礙成長要素
  • 法規及醫療費的給付
  • 美國國內的法規
  • 美國國外的法規
  • 美國國內的給付制度
  • 美國國外的給付制度

第4章 組織型判別技術

  • 移植上組織型判別所扮演的角色
  • 組織型判別技術
  • HLA 分析方法
  • 全球組織型判別市場
  • 各地區分析

第5章 與固態內臟器官的採購保存

  • 腦組織壞死定義
  • 受到移植的內臟器官
  • 美國的供給增加
  • 與移植的擴大管理
  • 供給管理
  • 美國國外的內臟器官採購
  • 美國的分配標準
  • EU的分配標準
  • 固態內臟器官的保存
  • 內臟器官保存方法的全球市場
  • 保存用液市場
  • 內臟器官保存用液的全球市場佔有率
  • 機器回流
  • 開發中的保存用液

第6章 組織產品

  • 組織產品的各地區市場
  • 軟組織的修復及替換
  • 全球軟組織市場預測:各地區
  • 心臟瓣膜
  • 角膜
  • 血液幹細胞
  • 生物性骨材市場
  • 皮膚移植
  • 血管組織移植

第7章 免疫抑制劑,抗感染藥,及移植後監測

  • 移植內臟器官的抗性
  • 通常的抗排斥藥物PROTOCOLS
  • 免疫抑制劑的種類 其他

第8章 替代設備及技術

  • 心臟移植替代治療方法
  • 整形外科設備市場機會
  • 整形外科置換術的產業大廠
  • 髖關節
  • 脊樑骨
  • 手足
  • 角膜移植替代治療方法
  • 小腸移植替代治療方法
  • 胰臟移植替代治療方法
  • 肝臟移植替代治療方法
  • 血管移植替代治療方法
  • 地區分析

第9章 開發中的新興治療與產品

  • 開發中的內臟器官保存液
  • 再生醫療
  • 幹細胞研究
  • 心血管治療的進步
  • 開發中的免疫抑制劑
  • 醫藥品開發平台開發
  • 義手·義足

第10章 企業名錄

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HLC012F

The global market for organ and tissue transplantation products and devices reached $55.6 billion in 2014. This market is estimated to grow at a compound annual growth rate (CAGR) of 6.8% to reach $62.9 billion by 2015 and $88.1 billion by 2020.

This report provides:

  • An overview of the global markets for organ and tissue transplantation and alternatives.
  • Analyses of global market trends, with data from 2014, estimates for 2015 and projections of CAGR through 2020.
  • Detailed examination of procurement and preservation, solid organ transplantation, tissue transplantation, immunosuppressives and other pharmaceuticals, post-transplantation concerns, as well as alternatives to transplantation.
  • Coverage of post-transplant immunosuppression and monitoring methods and post-transplant drug regimens and patient and graft survival rates.
  • In-depth analysis of the market's dynamics, specifically growth drivers, inhibitors, and opportunities
  • Comprehensive profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE OF REPORT

This report offers forecasts, by product segment, from 2015 through 2020, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.

Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells and altered cancer cells.

The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.

Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques and pharmaceuticals are highlighted.

Profiles of more than 50 leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies' available and emerging products.

An appendix featuring various terms and processes used in transplantation is provided at the end of the report.

This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.

ANALYST'S CREDENTIALS

Peggy S. Lehr is the BCC Research analyst for this report. Ms. Lehr has worked with the publishing arms of for-profit and not-for-profit organizations for more than 25 years, and she specializes in marketing reports on the medical industry. She has contributed several reports on the medical industry for BCC, including reports on the global market for catheters, the sterilization market, reports on pediatric and eldercare markets, cardiovascular surgical industry and her most recent report on the global allergy diagnosis and treatment market.

Table of Contents

CHAPTER 1 INTRODUCTION

  • REASONS FOR DOING THE STUDY
  • STUDY GOALS AND OBJECTIVES
  • SCOPE OF REPORT
  • METHODOLOGIES AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • COST OF CARE
  • GLOBAL MARKET
  • SOLID ORGAN PRESERVATION
  • IMMUNOSUPPRESSION
  • DONATION
  • SOFT TISSUE MARKET
  • ORGAN ALTERNATIVES
  • GLOBAL MARKET PROJECTIONS
  • SUMMARY TABLE PROJECTED GLOBAL MARKET FOR TRANSPLANTATION PRODUCTS AND DEVICES, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE PROJECTED GLOBAL MARKET SHARE OF TRANSPLANTATION PRODUCTS AND DEVICES, 2015 AND 2020 (%)

CHAPTER 3 INDUSTRY OVERVIEW

  • HISTORY OF TRANSPLANTATION
  • TABLE 1 TIMELINE OF ORGAN TRANSPLANTATION HISTORY, 1900-2012
  • INDUSTRY ACQUISITIONS
  • TABLE 2 SELECTED TRANSPLANT INDUSTRY ACQUISITIONS, 2010-EARLY 2015 ($ MILLIONS)
  • NECESSARY COMPONENTS TO ORGAN AND TISSUE TRANSPLANTATION
    • TISSUE TYPING
    • PRESERVATION
      • Tissue Preservation
    • IMMUNOSUPPRESSION
      • Newer Immunosuppressive Drugs
      • POSTOPERATIVE INFECTION CONTROL
  • OVERVIEW OF THE DONATION PROCESS
    • BLACK MARKET DONORS
  • THE TRANSPLANTATION PROCESS
    • PREPARATION
      • The Role of the Organ Procurement Organization
    • SURGERY
    • RECUPERATION
    • MAINTENANCE
  • SOLID ORGANS
    • COST OF SOLID ORGAN TRANSPLANTATION IN THE U.S.
    • TABLE 3 U.S. ORGAN/TISSUE TRANSPLANTS: AVERAGE FIRST YEAR COST, ESTIMATED NUMBER OF PROCEDURES, AND VALUE BY TYPE OF ORGAN TRANSPLANT, 2011
    • KIDNEY TRANSPLANTS IN THE U.S.
      • Living Donor Efforts
      • Necessary Inputs for Successful Kidney Transplantation
    • LIVER TRANSPLANTATION IN THE U.S.
      • Promising Treatments
      • Necessary Inputs for Successful Liver Transplantation
    • HEART TRANSPLANTS IN THE U.S.
      • Necessary Inputs for Successful Heart Transplantation
    • INTESTINE TRANSPLANTATION IN THE U.S.
      • Necessary Inputs for Successful Intestine Transplantation
    • PANCREAS TRANSPLANTATION IN THE U.S.
      • Necessary Inputs for Successful Pancreas Transplantation
  • TISSUE TRANSPLANTATION IN THE U.S.
  • TRANSPLANTATION TRENDS OUTSIDE THE U.S.
    • ORGAN DONATION IN EUROPE
    • TABLE 4 ORGAN DONATIONS IN EUROPE, BY TYPE, 2012-2013
      • Standards in Europe
      • Transplant Organizations in the EU
    • JAPANESE ORGAN TRANSPLANT CRITERIA
      • Tradition and Beliefs
      • Brain Death in Japan
      • Three Key Elements of Conventional Death in Japan
  • TRENDS IN LIVING AND CADAVERIC DONATIONS OUTSIDE THE U.S.
  • GLOBAL SOLID ORGAN TRANSPLANTATION
  • TABLE 5 GLOBAL ACTIVITY IN ORGAN TRANSPLANTATION, 2012
    • KIDNEY DONATIONS
    • LIVER DONATIONS
  • LIMITED ORGAN SUPPLY CURTAILS TRANSPLANTATIONS
    • LIVING DONOR PROGRAMS
  • KEY FACTORS IN INDUSTRY GROWTH
    • REDUCING DEMAND
    • INCREASING PATIENT SURVIVAL RATES
    • TABLE 6 U.S. GRAFT SURVIVAL RATES, BY ORGAN AND YEARS (%)
    • DEVELOPING ORGAN SUBSTITUTES
      • Organs from Animals: Xenotransplantation
        • Emotional/Ethical Implications of Xenotransplantation
      • Organ Primordia
    • ARTIFICIAL ORGANS
  • KEY FACTORS INHIBITING GROWTH
  • LACK OF DONORS
    • ALTERNATIVE THERAPIES
    • PHARMACEUTICAL TREATMENTS
    • CULTURAL STIGMAS
      • Opt-in Consent and Presumed Consent
      • Anatomical Intent and Payment for Organs in the U.S.
  • REGULATIONS AND REIMBURSEMENT
  • REGULATIONS IN THE U.S.
    • U.S. FEDERAL REGULATION OF HUMAN TISSUE
    • HISTORY OF REGULATION IN THE U.S.
  • REGULATIONS OUTSIDE THE U.S.
    • TRANSPLANT "TOURISM"
  • REIMBURSEMENT IN THE U.S.
    • ORGAN ACQUISITION COSTS
    • REIMBURSEMENT FOR HOSPITAL COSTS
    • REIMBURSEMENT FOR PHYSICIAN SERVICES
    • REIMBURSEMENT FOR IMMUNOSUPPRESSANTS IN THE U.S.
    • TABLE 7 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*
    • TABLE 8 OVERVIEW OF MEDICARE IMMUNOSUPPRESSIVE DRUG COVERAGE
  • REIMBURSEMENT OUTSIDE THE U.S.
    • TREATMENT IN EU COUNTRIES

CHAPTER 4 TISSUE TYPING TECHNOLOGIES

  • ROLE OF TISSUE TYPING IN TRANSPLANTATION
  • TISSUE TYPING TECHNOLOGIES
  • TABLE 9 TISSUE TYPING TECHNOLOGIES
  • HLA ANALYSIS METHODS
    • SEQUENCE-SPECIFIC TYPING
      • Panel Reactive Antibodies (PRA)
      • Sequence-Specific Primer (SSP)
      • Sequence-Specific Oligonucleotide Probes (SSOP)
    • REFERENCE STRAND-BASED MEDIATED CONFORMATION ANALYSIS (RSCA)
  • GLOBAL TISSUE TYPING MARKET
  • TABLE 10 PROJECTED GLOBAL MARKET FOR TISSUE TYPING, THROUGH 2020 ($ MILLIONS)
    • COMMERCIALIZATION OPPORTUNITIES IN TISSUE TYPING
    • MARKET LEADERS
    • FIGURE 1 GLOBAL MARKET SHARES IN TISSUE TYPING TECHNOLOGIES BY MARKET LEADER, 2014 (%)
    • REGIONAL ANALYSIS
    • TABLE 11 PROJECTED GLOBAL TISSUE TYPING MARKET, BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 5 SOLID ORGAN PROCUREMENT AND PRESERVATION

  • DEFINITION OF BRAIN DEATH
  • ORGANS OBTAINED FOR TRANSPLANT
  • INCREASING SUPPLY IN THE U.S.
  • THE TRANSPLANT GROWTH AND MANAGEMENT COLLABORATIVE
  • SUPPLY MANAGEMENT
    • REDUCING WASTE AND REJECTION
    • FIGHTING REJECTION
    • TABLE 12 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2007-2013
    • INCREASING THE HARVEST
    • TABLE 13 PERCENT OF U.S. ORGAN DISCARDS, BY TYPE, 2012 (%)
    • NON-BEATING HEART DONORS
    • LESS WASTE
  • ORGAN PROCUREMENT OUTSIDE THE U.S.
    • MANAGEMENT OF DONATED ORGANS IN THE EU
    • CHINA
    • JAPAN
  • ALLOCATION CRITERIA IN THE U.S.
  • TABLE 14 MEDIAN U.S. WAITLIST TIME FOR POTENTIAL RECIPIENTS, BY ORGAN AND NUMBER OF MONTHS, 2008 (NO. OF MONTHS)
    • MELD/PELD SYSTEM
  • ALLOCATION CRITERIA IN THE EU
    • MELD/PELD IN THE U.K.
  • SOLID ORGAN PRESERVATION
    • TABLE 15 COLD ISCHEMIA TIME FOR TRANSPLANTED ORGANS (HOURS)
  • GLOBAL MARKET FOR ORGAN PRESERVATION METHODS
  • TABLE 16 PROJECTED GLOBAL MARKET FOR ORGAN PRESERVATION METHODS, THROUGH 2020 ($ MILLIONS)
    • SIMPLE STATIC COLD STORAGE
    • TABLE 17 OPTIMAL PRESERVATION SOLUTION DESIGN
      • Rinse and Preservation Solutions 5
      • TABLE 18 MAJOR ORGAN PRESERVATION SOLUTIONS
    • KIDNEY COLD-STORAGE METHODS STUDY
    • TYPES OF COLD STORAGE SOLUTIONS
      • Celsior
      • Euro Collins Solution
      • Custodiol
      • Hypothermosol FRS
      • Perfadex
      • UW Solution
      • KPS-1 Kidney Perfusion Solution
      • Lifor
  • MARKET FOR PRESERVATION SOLUTIONS
  • TABLE 19 PROJECTED GLOBAL MARKET FOR SOLID ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORTH COCKTAIL) BY GEOGRAPHIC REGION, THROUGH 2020 ($ MILLIONS)
  • GLOBAL MARKET SHARE OF ORGAN PRESERVATION SOLUTIONS
  • FIGURE 2 GLOBAL MARKET SHARE OF ORGAN PRESERVATION SOLUTIONS 2013 (%)
  • MACHINE PERFUSION
    • EARLY MACHINE PERFUSION
    • CURRENT MACHINE PERFUSION
    • TABLE 20 ADVANTAGES AND DISADVANTAGES OF MACHINE PERFUSION
    • MARKET FOR MACHINE PERFUSION/ORGAN TRANSPORT SYSTEMS
    • TABLE 21 PROJECTED GLOBAL MARKET FOR MACHINE PERFUSION /ORGAN TRANSPORT SYSTEMS, THROUGH 2020 ($ MILLIONS)
    • ORGAN TRANSPORT AND PERFUSION SYSTEMS
      • Sherpa Perfusion Systems
      • Waves Renal Perfusion
      • LifePort
      • KidneyAssist
      • LifeCradle
      • Organ Care System
  • PRESERVATION SOLUTIONS IN DEVELOPMENT
    • KYOTO UNIVERSITY SOLUTION
    • IGL-1 SOLUTION
    • SOMAH SOLUTION
    • VASOWAVE

CHAPTER 6 TISSUE PRODUCTS

  • TABLE 22 PROJECTED GLOBAL TISSUE GRAFTING MARKET, BY TISSUE TYPE THROUGH 2020 ($ MILLIONS)
  • GLOBAL TISSUE MARKET, BY REGION
  • TABLE 23 PROJECTED GROWTH IN TISSUE MARKET REVENUES, BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 3 GLOBAL TISSUE MARKET SHARES BY REGION, 2015 AND 2020 (%)
  • SOFT TISSUE REPAIR AND REPLACEMENT
    • CARTILAGE REPAIR AND REPLACEMENT
    • OTHER SOFT TISSUE REPAIR AND REPLACEMENT
    • TABLE 24 CARTILAGE AND SOFT TISSUE BIOLOGICS AND BIOMATERIALS
    • PROJECTED GLOBAL SOFT TISSUE MARKET
    • TABLE 25 PROJECTED GLOBAL MARKET FOR SOFT TISSUE REPAIR AND REPLACEMENT, THROUGH 2020 ($ MILLIONS)
  • PROJECTED GLOBAL SOFT TISSUE MARKET, BY REGION
  • TABLE 26 PROJECTED GLOBAL MARKET FOR SOFT TISSUE REPAIR AND REPLACEMENT, BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 4 GLOBAL SOFT TISSUE MARKET, BY REGION, IN 2015 AND 2020 (%)
  • HEART VALVES
    • MECHANICAL
    • BIOLOGICAL/TISSUE
    • HOMOGRAFT
    • TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)
    • GROWTH IN THE HEART VALVE MARKET
    • TABLE 27 GLOBAL HEART VALVE MARKET, THROUGH 2020 ($ MILLIONS)
    • HEART VALVE MARKET LEADERS
    • FIGURE 5 LEADING HEART VALVE SUPPLIERS, 2014 (%)
    • GLOBAL HEART VALVE MARKET, BY REGION
    • TABLE 28 PROJECTED GLOBAL MARKET FOR HEART VALVES, BY REGION, THROUGH 2020 ($ MILLIONS)
    • HEART VALVE MARKET IN THE FUTURE
  • CORNEA
    • CORNEAL TRANSPLANTS IN THE U.S.
    • GLOBAL CORNEAL TRANSPLANT MARKET
    • TABLE 29 PROJECTED GLOBAL GROWTH OF CORNEAL TRANSPLANT MARKET, THROUGH 2020* ($ MILLIONS)
  • BLOOD STEM CELLS
    • HISTORY
      • First Successful Transplant
      • Donor Registries
    • GLOBAL STEM CELL TRANSPLANT ACTIVITY
    • INDICATIONS FOR STEM CELL TRANSPLANTS
    • REJECTION
    • TYPES OF STEM CELLS
      • Bone Marrow
      • Peripheral Blood
      • Umbilical Cord Blood
    • GLOBAL MARKET FOR BLOOD STEM CELL TRANSPLANTATION
    • TABLE 30 PROJECTED GLOBAL MARKET FOR BLOOD STEM CELL TRANSPLANTATION, THROUGH 2020 ($ MILLIONS)
    • WORLDWIDE INCIDENCE OF PROCEDURES
  • THE ORTHOBIOLOGICS MARKET
  • TABLE 31 PROJECTED GLOBAL MARKET FOR ORTHOBIOLOGICAL PRODUCTS, THROUGH 2020* ($ MILLIONS)
    • BASE TISSUE
    • BONE PUTTY/DEMINERALIZED BONE MATRIX (DBM) PRODUCTS
    • MACHINED IMPLANTS
    • TABLE 32 HUMAN BONE PRODUCTS AND MARKETERS
    • SYNTHETIC BONE REPLACEMENTS
    • TABLE 33 SYNTHETIC BONE-REPLACEMENT PRODUCTS AND MARKETERS
  • SKIN GRAFTS
    • APPLICATIONS
    • MARKET FOR SKIN GRAFTS
    • TABLE 34 PROJECTED GLOBAL GROWTH OF SKIN GRAFTS, THROUGH 2020 ($ MILLIONS)
  • VASCULAR TISSUE TRANSPLANTATION
    • PRODUCTS
    • GLOBAL MARKET FOR VASCULAR TISSUE
    • TABLE 35 PROJECTED GLOBAL VASCULAR TISSUE TRANSPLANTATION MARKET, THROUGH 2020 ($ MILLIONS)

CHAPTER 7 IMMUNOSUPPRESSANTS, ANTI-INFECTIVES AND POST-TRANSPLANT MONITORING

  • TOLERANCE OF TRANSPLANTED ORGANS
    • ANTISENSE THERAPY
    • COSTIMULATION
    • CHIMERISM
  • COMMON ANTI-REJECTION DRUG PROTOCOLS
  • TYPES OF IMMUNOSUPPRESSANTS
  • TABLE 36 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS USED IN TRANSPLANTS, BY TYPE, THROUGH 2020 ($ MILLIONS)
  • FIGURE 6 PROJECTED GLOBAL MARKET SHARES OF IMMUNOSUPPRESSIVES BY TYPE, THROUGH 2020 (%)
  • TABLE 37 IMMUNOSUPPRESSANT DRUGS APPROVED IN THE U.S., THE EU, AND JAPAN, THROUGH 2014
  • TABLE 38 IMMUNOSUPPRESSANTS BY DRUG CLASS, GENERIC NAME, BRAND NAME, AND MANUFACTURER
  • CALCINEURIN INHIBITORS
    • CYCLOSPORINE
      • Generic Cyclosporine
    • TACROLIMUS
    • TABLE 39 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 ($ MILLIONS)
  • ANTI-PROLIFERATIVE AGENTS
    • AZATHIOPRINE
    • MYCOPHENOLATE MOFETIL
    • MYCOPHENOLATE SODIUM
    • TABLE 40 GLOBAL MARKET FOR ANTI-PROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 ($ MILLIONS)
  • M-TOR INHIBITORS
    • SIROLIMUS
    • TEMSIROLIMUS
    • EVEROLIMUS (CERTICAN/ZORTRESS)
    • TABLE 41 PROJECTED GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 ($ MILLIONS)
  • MONOCLONAL AND POLYCLONAL ANTIBODY PRODUCTS
  • TABLE 42 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION
    • POLYCLONAL ANTIBODY PRODUCTS
      • Thymoglobulin
      • Atgam
      • TABLE 43 PROJECTED GLOBAL MARKET FOR POLYCLONAL ANTIBODY PRODUCTS, THROUGH 2020 ($ MILLIONS)
    • MONOCLONAL ANTIBODY PRODUCTS
      • Off-label Medications
        • Rituximab
  • T-CELL COSTIMULATION BLOCKER
  • TABLE 44 PROJECTED GLOBAL MARKET FOR T-CELL COSTIMULATION BLOCKERS, THROUGH 2020 ($ MILLIONS)
  • TREATMENTS BY STAGE OF PROCEDURE
    • INDUCTION THERAPY
      • Disadvantages of Induction Therapy
      • Standard Treatments
      • TABLE 45 IMMUNOSUPPRESSANT USE FOR INDUCTION BY ORGAN IN U.S., 2012* (%)
  • MAINTENANCE THERAPY
  • TABLE 46 IMMUNOSUPPRESSANT USE FOR MAINTENANCE (UP TO 2 YEARS POST-TRANSPLANT) BY ORGAN, 2010* (%)
  • IMMUNOSUPPRESSANT USE IN PEDIATRIC TRANSPLANTATION
  • ADVANCES IN POST-OPERATIVE DESENSITIZATION
  • GLOBAL IMMUNOSUPPRESSANT MARKET
  • TABLE 47 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 7 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, 2015 AND 2020 (%)
  • ANTI-INFECTIVES AND POST-TRANSPLANT MONITORING IN ORGAN AND TISSUE TRANSPLANTATION
    • ANTI-INFECTIVES AND IMMUNOSUPPRESSANTS
    • TABLE 48 COMMON ANTI-INFECTIVE AND IMMUNOSUPPRESSANT AGENTS AND INTERACTIONS, 2012*
      • Market for Anti-infectives in transplantation
      • TABLE 49 POST-TRANSPLANT INFECTIONS BY TYPE OF TRANSPLANT, WITH COMMON TIME FRAMES FOR INFECTION
    • POST-TRANSPLANT MONITORING
    • TABLE 50 RECOMMENDED POST-TRANSPLANT CARE, 2012

CHAPTER 8 ALTERNATIVE DEVICES AND TECHNOLOGIES

  • TABLE 51 PROJECTED GLOBAL MARKET FOR TRANSPLANTATION ALTERNATIVE DEVICES, THROUGH 2020 ($ MILLIONS)
  • ALTERNATIVES TO HEART TRANSPLANTATION
    • MEDICAL
    • SURGICAL
      • Cardiac Support Devices
    • MECHANICAL
      • Total Artificial Heart
      • Ventricular Assist Devices
        • Generations of Designs
        • TABLE 52 GLOBAL MARKET FOR ARTIFICIAL HEART DEVICES, THROUGH 2020 ($ MILLIONS)
    • TOTAL ARTIFICIAL HEARTS
    • TABLE 53 GLOBAL MARKET FOR TOTAL ARTIFICIAL HEARTS, THROUGH 2020 ($ MILLIONS)
    • VENTRICULAR ASSIST DEVICES
      • Regeneration Instead of Replacement
      • TABLE 54 GLOBAL MARKET FOR VADS, THROUGH 2020 ($ MILLIONS)
      • VAD as Destination Therapy
      • VAD Development Outside the U.S.
  • OPPORTUNITIES IN THE ORTHOPEDIC DEVICE MARKET
  • TABLE 55 SELECTED GLOBAL COMMERCIAL OPPORTUNITIES FOR NEW DEVICES IN THE FUTURE
  • TABLE 56 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC DEVICES USED IN TRANSPLANTATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 8 GLOBAL MARKET FOR ORTHOPEDIC DEVICES, BY TYPE, 2015 AND 2020 (%)
  • MARKET LEADERS IN ORTHOPEDIC REPLACEMENTS
  • FIGURE 9 ORTHOPEDIC REPLACEMENT DEVICE MARKET, BY COMPANY MARKET SHARE, 2014 (%)
  • HIP
    • COSTS OF HIP REPLACEMENT SURGERIES
    • ALTERNATIVES TO HIP REPLACEMENT/RECONSTRUCTION
    • TABLE 57 PROJECTED GLOBAL MARKET FOR HIP REPLACEMENTS, THROUGH 2020 ($ MILLIONS)
  • KNEE
  • TABLE 58 PROJECTED GLOBAL MARKET FOR KNEE REPLACEMENTS, THROUGH 2020 ($ MILLIONS)
  • SPINE
  • TABLE 59 PROJECTED GLOBAL MARKET FOR SPINAL RECONSTRUCTIVE PRODUCTS, THROUGH 2020 ($ MILLIONS)
  • FIGURE 10 GLOBAL MARKET SHARES OF THE SPINAL RECONSTRUCTION MARKET BY COMPANY, 2013 (%)
  • EXTREMITIES
    • MARKET DRIVERS
    • TABLE 60 PROJECTED GLOBAL MARKET FOR EXTREMITY REPAIR/REPLACEMENTS, THROUGH 2020 ($ MILLIONS)
  • ALTERNATIVES TO CORNEAL TRANSPLANTATION
    • SURGICAL
    • TABLE 61 THERAPEUTIC INDICATIONS FOR PTK
      • Cellular Retinal Transplants
      • Electronic Implants
  • ALTERNATIVES TO INTESTINAL TRANSPLANTATION
    • MEDICAL
  • ALTERNATIVES TO PANCREAS TRANSPLANTATION
    • SURGICAL
      • Islet Cell Transplantation
    • BIOARTIFICIAL PANCREAS
  • ALTERNATIVES TO LIVER TRANSPLANTATION
  • TABLE 62 INDICATIONS FOR BIOARTIFICIAL LIVER TRANSPLANTATION
  • ALTERNATIVES TO VASCULAR TRANSPLANTATION
    • TISSUE ENGINEERING OF VASCULAR GRAFTS
    • GENE THERAPY
  • REGIONAL ANALYSIS
  • TABLE 63 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC AND CARDIAC ALTERNATIVE THERAPIES, BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 11 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC IMPLANT PRODUCTS, BY REGION, 2015 AND 2020 (%)

CHAPTER 9 EMERGING PROCEDURES AND PRODUCTS IN DEVELOPMENT

  • ORGAN PRESERVATION SOLUTIONS IN DEVELOPMENT
    • KYOTO UNIVERSITY SOLUTION
    • IGL-1 SOLUTION
    • SOMAH SOLUTION
    • VASOWAVE
    • ISOGARCINOL
  • REGENERATIVE MEDICINE
    • APPLICATIONS IN LIVER TRANSPLANTS
    • ISLET CELL TRANSPLANTATION
    • CELLULAR THERAPIES
    • TABLE 64 TYPES OF REGENERATIVE CELLULAR THERAPIES
    • KIDNEY TRANSPLANT
      • New Molecule for Stable Immunological Tolerance after Kidney Transplantation
      • Veloxis Pharmaceuticals
      • Alexion
    • CYTOMEGALOVIRUS TREATMENTS
      • Astellas Pharmaceuticals
    • CORNEAL TRANSPLANTS
      • Stem Cells and Bioengineering
  • STEM CELL RESEARCH
    • STEM CELL RESEARCH FUNDING IN THE U.S,
  • ADVANCES IN CARDIOVASCULAR TREATMENTS
    • FIBROBLAST GROWTH FACTORS
    • CARDIOVASCULAR BIOTHERAPEUTIC INC.
  • IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT
  • TABLE 65 SELECTED IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT, 2015
  • PHARMACEUTICAL PIPELINE DEVELOPMENT
  • TABLE 66 PHARMACEUTICAL PIPELINE/DEVICE BY MANUFACTURER, TYPE OF PRODUCT, INDICATIONS FOR USE, AND STAGE OF CLINICAL TESTING
  • EXTREMITY REPAIR/REPLACEMENT
    • WRIGHT MEDICAL TECHNOLOGY
      • Simpliciti
      • Augment Bone Graft

CHAPTER 10 COMPANY DIRECTORY

  • TISSUE TYPING/DIAGNOSTICS
    • ABBOTT LABORATORIES
      • Business Overview
      • Products
    • BIORAD LABORATORIES
      • Business Overview
      • Products
    • CELERA CORP. (QUEST DIAGNOSTICS)
      • Business Overview
      • Products
    • DIAGAST
      • Business Overview
      • Products
    • HOLOGIC (GEN-PROBE)
      • Business Overview
      • Products
    • LIFE TECHNOLOGIES (PART OF THERMO FISHER SCIENTIFIC)
      • Business Overview
      • Products
    • LUMINEX CORP.
      • Business Overview
      • Products
    • ONE LAMBDA INC. (THERMO FISHER SCIENTIFIC)
      • Business Overview
      • Products
    • PROTEOME SCIENCES, PLC
      • Business Overview
      • Products
    • PRESERVATION SOLUTIONS (SOLID ORGAN/CELL/TISSUE)/ TRANSPORT SYSTEMS
    • BRIDGE TO LIFE LTD.
      • Business Overview
      • Products
    • CRYOLIFE INC.
      • Business Overview
      • Products
    • DR. F. KOHLER CHEMIE GMBH
      • Business Overview
      • Products
    • INSTITUT GEORGES LOPEZ (IGL)
      • Business Overview
      • Products
    • LIFEBLOOD MEDICAL INC./CELL PRESERVATION SOLUTIONS
      • Business Overview
      • Products
    • LIFELINE SCIENTIFIC
      • Business Overview
      • Products
    • ORGAN ASSIST
      • Business Overview
      • Products
    • ORGAN TRANSPORT SYSTEMS
      • Business Overview
      • Products
    • PARAGONIX TECHNOLOGIES
      • Business Overview
      • Products
      • PRESERVATION SOLUTIONS INC
      • Business Overview
      • Products
    • SANOFI (SEE GENZYME IN TRANSPLANT PHARMACEUTICALS)
    • TRANSMEDICS INC
      • Business Overview
      • Products
      • XVIVO PERFUSION AB
      • Business Overview
      • Products
  • TRANSPLANT PHARMACEUTICALS (IMMUNOSUPPRESSANTS, POST-TRANSPLANT PHARMACEUTICALS)
    • AMGEN INC.
      • Business Overview
      • Products
    • ASTELLAS PHARMA INC.
      • Business Overview
      • Products
    • BRISTOL-MYERS SQUIBB
      • Business Overview
      • Products
    • GENZYME (A SANOFI COMPANY)
      • Business Overview
      • Products
    • JANSSEN BIOTECH
      • Business Overview
      • Products
    • JANSSEN CILAG (SEE JANSSEN BIOTECH)
    • KIADIS PHARMA
      • Business Overview
      • Products
    • NOVARTIS INTERNATIONAL AG
      • Business Overview
      • Products
    • PFIZER INC. 69
      • Business Overview
      • Products
    • ROCHE PHARMACEUTICALS
      • Business Overview
      • Products
    • VELOXIS PHARMACEUTICALS (FORMERLY LIFECYCLE PHARMA A/S)
      • Business Overview
      • Products
  • MECHANICAL HEART IMPLANTS
    • ABIOMED
      • Business Overview
      • Products
    • BERLIN HEART GMBH
      • Business Overview
      • Products
    • HEARTWARE INTERNATIONAL INC.
      • Business Overview
      • Products
    • SYNCARDIA SYSTEMS INC.
      • Business Overview
      • Products
    • TERUMO HEART
      • Business Overview
      • Products
    • THORATEC CORP.
      • Business Overview
      • Products
  • HEART VALVES
    • BOSTON SCIENTIFIC
      • Business Overview
      • Products
    • EDWARDS LIFESCIENCES
      • Business Overview
      • Products
    • MEDTRONIC
      • Business Overview
      • Products
    • SORIN S.P.A.
      • Business Overview
      • Products
    • TERUMO CARDIOVASCULAR SYSTEMS CORP.
      • Business Overview
      • Products
  • JOINT/ORTHOPEDIC IMPLANTS
    • ALPHATEC SPINE
      • Business Overview
      • Products
    • ARTHREX INC.
      • Business Overview
      • Products
    • BIOMET, INC
      • Business Overview
      • Products
    • CONMED-LINVATEC CORP.
      • Business Overview
      • Products
    • DEPUY SYNTHES
      • Business Overview
      • Products
    • DJO SURGICAL
      • Business Overview
      • Products
    • EXACTECH
      • Business Overview
      • Products
    • INTEGRA LIFESCIENCE
      • Business Overview
      • Products
    • K2M GROUP HOLDINGS INC.
      • Business Overview
      • Products
    • LDR HOLDING CORP.
      • Business Overview
      • Products
    • NUVASIVE INC.
      • Business Overview
      • Products
    • ORTHOFIX INTERNATIONAL
      • Business Overview
      • Products
    • RTI BIOLOGICS
      • Business Overview
      • Products
    • SMITH & NEPHEW, PLC
      • Business Overview
      • Products
    • STRYKER
      • Business Overview
      • Products
    • TORNIER INC. (U.S.)
      • Business Overview
      • Products
    • W.L. GORE & ASSOCIATES
      • Business Overview
      • Products
    • WRIGHT MEDICAL TECHNOLOGY INC.
      • Business Overview
      • Products
    • ZIMMER HOLDINGS INC.
      • Business Overview
      • Products
  • TISSUE/BONE REGENERATIVE PRODUCTS
    • ACELITY (FORMERLY KINETIC CONCEPTS INC. AND LIFECELL)
      • Business Overview
      • Products
    • ALLOSOURCE
      • Business Overview
      • Products
    • BAXTER BIOSURGERY (BAXTER AND SYNOVIS SURGICAL INNOVATIONS)
      • Business Overview
      • Products
    • BIOMATLANTE
      • Business Overview
      • Products
    • BIOMIMETIC THERAPEUTICS INC. (SEE WRIGHT MEDICAL GROUP)
    • BIOTISSUE TECHNOLOGIES GMBH
      • Business Overview
      • Products
    • BONALIVE BIOMATERIALS LTD.
      • Business Overview
      • Products
    • CITAGENIX INC.
      • Business Overview
      • Products
    • COOK MEDICAL
      • Business Overview
      • Products
    • CURASAN AG
      • Business Overview
      • Products
    • DISCGENICS
      • Business Overview
      • Products
    • ETEX CORP.
      • Business Overview
      • Products
    • EXABONE GMBH
      • Business Overview
      • Products
    • FORTICELL BIOSCIENCE (FORMERLY ORTEC INTERNATIONAL, INC.)
      • Business Overview
      • Products
    • GLOBUS MEDICAL
      • Business Overview
      • Products
    • GRAFTYS
      • Business Overview
      • Products
    • DSM BIOMEDICAL (FORMERLY KENSEY NASH CORP.)
      • Business Overview
      • Products
    • MEDTRONIC INC.
      • Business Overview
      • Products
    • MOLNLYCKE HEALTH CARE
      • Business Overview
      • Products
    • MUSCULOSKELETAL TRANSPLANT FOUNDATION
      • Business Overview
      • Products
    • ORTHOVITA INC. (SEE STRYKER)
    • OSIRIS THERAPEUTICS INC.
      • Business Overview
      • Products
    • OSTEOGENICS BIOMEDICAL INC.
      • Business Overview
      • Products
    • TEI BIOSCIENCES
      • Business Overview
      • Products
    • TEKNIMED
      • Business Overview
      • Products
    • TETEC TISSUE ENGINEERING TECHNOLOGIES AG
      • Business Overview
      • Products
    • TIGENIX N.V.
      • Business Overview
      • Products
    • VIACYTE INC.
      • Business Overview
      • Products

CHAPTER 11 APPENDIX

  • TABLE 67 DEFINITIONS

LIST OF TABLES

  • SUMMARY TABLE PROJECTED GLOBAL MARKET FOR TRANSPLANTATION PRODUCTS AND DEVICES, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 TIMELINE OF ORGAN TRANSPLANTATION HISTORY, 1900-2012
  • TABLE 2 SELECTED TRANSPLANT INDUSTRY ACQUISITIONS, 2010-EARLY 2015 ($ MILLIONS)
  • TABLE 3 U.S. ORGAN/TISSUE TRANSPLANTS: AVERAGE FIRST YEAR COST, ESTIMATED NUMBER OF PROCEDURES, AND VALUE BY TYPE OF ORGAN TRANSPLANT, 2011
  • TABLE 4 ORGAN DONATIONS IN EUROPE, BY TYPE, 2012-2013
  • TABLE 5 GLOBAL ACTIVITY IN ORGAN TRANSPLANTATION, 2012
  • TABLE 6 U.S. GRAFT SURVIVAL RATES, BY ORGAN AND YEARS (%)
  • TABLE 7 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*
  • TABLE 8 OVERVIEW OF MEDICARE IMMUNOSUPPRESSIVE DRUG COVERAGE 3
  • TABLE 9 TISSUE TYPING TECHNOLOGIES
  • TABLE 10 PROJECTED GLOBAL MARKET FOR TISSUE TYPING, THROUGH 2020 ($ MILLIONS)
  • TABLE 11 PROJECTED GLOBAL TISSUE TYPING MARKET, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 12 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2007-2013
  • TABLE 13 PERCENT OF U.S. ORGAN DISCARDS, BY TYPE, 2012 (%)
  • TABLE 14 MEDIAN U.S. WAITLIST TIME FOR POTENTIAL RECIPIENTS, BY ORGAN AND NUMBER OF MONTHS, 2008 (NO. OF MONTHS)
  • TABLE 15 COLD ISCHEMIA TIME FOR TRANSPLANTED ORGANS (HOURS)
  • TABLE 16 PROJECTED GLOBAL MARKET FOR ORGAN PRESERVATION METHODS, THROUGH 2020 ($ MILLIONS)
  • TABLE 17 OPTIMAL PRESERVATION SOLUTION DESIGN
  • TABLE 18 MAJOR ORGAN PRESERVATION SOLUTIONS
  • TABLE 19 PROJECTED GLOBAL MARKET FOR SOLID ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORTH COCKTAIL) BY GEOGRAPHIC REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 20 ADVANTAGES AND DISADVANTAGES OF MACHINE PERFUSION
  • TABLE 21 PROJECTED GLOBAL MARKET FOR MACHINE PERFUSION /ORGAN TRANSPORT SYSTEMS, THROUGH 2020 ($ MILLIONS)
  • TABLE 22 PROJECTED GLOBAL TISSUE GRAFTING MARKET, BY TISSUE TYPE THROUGH 2020 ($ MILLIONS)
  • TABLE 23 PROJECTED GROWTH IN TISSUE MARKET REVENUES, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 24 CARTILAGE AND SOFT TISSUE BIOLOGICS AND BIOMATERIALS
  • TABLE 25 PROJECTED GLOBAL MARKET FOR SOFT TISSUE REPAIR AND REPLACEMENT, THROUGH 2020 ($ MILLIONS)
  • TABLE 26 PROJECTED GLOBAL MARKET FOR SOFT TISSUE REPAIR AND REPLACEMENT, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 27 GLOBAL HEART VALVE MARKET, THROUGH 2020 ($ MILLIONS)
  • TABLE 28 PROJECTED GLOBAL MARKET FOR HEART VALVES, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 29 PROJECTED GLOBAL GROWTH OF CORNEAL TRANSPLANT MARKET, THROUGH 2020* ($ MILLIONS)
  • TABLE 30 PROJECTED GLOBAL MARKET FOR BLOOD STEM CELL TRANSPLANTATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 31 PROJECTED GLOBAL MARKET FOR ORTHOBIOLOGICAL PRODUCTS, THROUGH 2020* ($ MILLIONS)
  • TABLE 32 HUMAN BONE PRODUCTS AND MARKETERS
  • TABLE 33 SYNTHETIC BONE-REPLACEMENT PRODUCTS AND MARKETERS
  • TABLE 34 PROJECTED GLOBAL GROWTH OF SKIN GRAFTS, THROUGH 2020 ($ MILLIONS)
  • TABLE 35 PROJECTED GLOBAL VASCULAR TISSUE TRANSPLANTATION MARKET, THROUGH 2020 ($ MILLIONS)
  • TABLE 36 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS USED IN TRANSPLANTS, BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 37 IMMUNOSUPPRESSANT DRUGS APPROVED IN THE U.S., THE EU, AND JAPAN, THROUGH 2014
  • TABLE 38 IMMUNOSUPPRESSANTS BY DRUG CLASS, GENERIC NAME, BRAND NAME, AND MANUFACTURER
  • TABLE 39 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 ($ MILLIONS)
  • TABLE 40 GLOBAL MARKET FOR ANTI-PROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 ($ MILLIONS)
  • TABLE 41 PROJECTED GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2020 ($ MILLIONS)
  • TABLE 42 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION
  • TABLE 43 PROJECTED GLOBAL MARKET FOR POLYCLONAL ANTIBODY PRODUCTS, THROUGH 2020 ($ MILLIONS)
  • TABLE 44 PROJECTED GLOBAL MARKET FOR T-CELL COSTIMULATION BLOCKERS, THROUGH 2020 ($ MILLIONS)
  • TABLE 45 IMMUNOSUPPRESSANT USE FOR INDUCTION BY ORGAN IN U.S., 2012* (%)
  • TABLE 46 IMMUNOSUPPRESSANT USE FOR MAINTENANCE (UP TO 2 YEARS POST-TRANSPLANT) BY ORGAN, 2010* (%)
  • TABLE 47 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 48 COMMON ANTI-INFECTIVE AND IMMUNOSUPPRESSANT AGENTS AND INTERACTIONS, 2012*
  • TABLE 49 POST-TRANSPLANT INFECTIONS BY TYPE OF TRANSPLANT, WITH COMMON TIME FRAMES FOR INFECTION 11
  • TABLE 50 RECOMMENDED POST-TRANSPLANT CARE, 2012
  • TABLE 51 PROJECTED GLOBAL MARKET FOR TRANSPLANTATION ALTERNATIVE DEVICES, THROUGH 2020 ($ MILLIONS)
  • TABLE 52 GLOBAL MARKET FOR ARTIFICIAL HEART DEVICES, THROUGH 2020 ($ MILLIONS)
  • TABLE 53 GLOBAL MARKET FOR TOTAL ARTIFICIAL HEARTS, THROUGH 2020 ($ MILLIONS)
  • TABLE 54 GLOBAL MARKET FOR VADS, THROUGH 2020 ($ MILLIONS)
  • TABLE 55 SELECTED GLOBAL COMMERCIAL OPPORTUNITIES FOR NEW DEVICES IN THE FUTURE
  • TABLE 56 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC DEVICES USED IN TRANSPLANTATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 57 PROJECTED GLOBAL MARKET FOR HIP REPLACEMENTS, THROUGH 2020 ($ MILLIONS)
  • TABLE 58 PROJECTED GLOBAL MARKET FOR KNEE REPLACEMENTS, THROUGH 2020 ($ MILLIONS)
  • TABLE 59 PROJECTED GLOBAL MARKET FOR SPINAL RECONSTRUCTIVE PRODUCTS, THROUGH 2020 ($ MILLIONS)
  • TABLE 60 PROJECTED GLOBAL MARKET FOR EXTREMITY REPAIR/REPLACEMENTS, THROUGH 2020 ($ MILLIONS)
  • TABLE 61 THERAPEUTIC INDICATIONS FOR PTK
  • TABLE 62 INDICATIONS FOR BIOARTIFICIAL LIVER TRANSPLANTATION
  • TABLE 63 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC AND CARDIAC ALTERNATIVE THERAPIES, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 64 TYPES OF REGENERATIVE CELLULAR THERAPIES
  • TABLE 65 SELECTED IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT, 2015
  • TABLE 66 PHARMACEUTICAL PIPELINE/DEVICE BY MANUFACTURER, TYPE OF PRODUCT, INDICATIONS FOR USE, AND STAGE OF CLINICAL TESTING
  • TABLE 67 DEFINITIONS

LIST OF FIGURES

  • SUMMARY FIGURE PROJECTED GLOBAL MARKET SHARE OF TRANSPLANTATION PRODUCTS AND DEVICES, 2015 AND 2020 (%)
  • FIGURE 1 GLOBAL MARKET SHARES IN TISSUE TYPING TECHNOLOGIES BY MARKET LEADER, 2014 (%)
  • FIGURE 2 GLOBAL MARKET SHARE OF ORGAN PRESERVATION SOLUTIONS 2013 (%)
  • FIGURE 3 GLOBAL TISSUE MARKET SHARES BY REGION, 2015 AND 2020 (%)
  • FIGURE 4 GLOBAL SOFT TISSUE MARKET, BY REGION, IN 2015 AND 2020 (%)
  • FIGURE 5 LEADING HEART VALVE SUPPLIERS, 2014 (%)
  • FIGURE 6 PROJECTED GLOBAL MARKET SHARES OF IMMUNOSUPPRESSIVES BY TYPE, THROUGH 2020 (%)
  • FIGURE 7 PROJECTED GLOBAL MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, 2015 AND 2020 (%)
  • FIGURE 8 GLOBAL MARKET FOR ORTHOPEDIC DEVICES, BY TYPE, 2015 AND 2020 (%)
  • FIGURE 9 ORTHOPEDIC REPLACEMENT DEVICE MARKET, BY COMPANY MARKET SHARE, 2014 (%)
  • FIGURE 10 GLOBAL MARKET SHARES OF THE SPINAL RECONSTRUCTION MARKET BY COMPANY, 2013 (%)
  • FIGURE 11 PROJECTED GLOBAL MARKET FOR ORTHOPEDIC IMPLANT PRODUCTS, BY REGION, 2015 AND 2020 (%)
Back to Top